ÂÜÀòÂÒÂ×

Jill Broadfoot is the current Chief Financial Officer at aTyr Pharma. Jill has previously held various finance leadership positions at Otonomy, Inc, GW Pharmaceuticals, and Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc.

Broadfoot began their career in finance at aTyr Pharma in May 2016 as the VP US Corporate Controller. In this role, they were responsible for building the finance and accounting capabilities needed to support GW's growing US operations.

In January 2017, Broadfoot transitioned to CFO at Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc. In this role, they were responsible for the formulation, manufacture, marketing and distribution of a unique line of safe and efficacious herbal remedies in the United States.

Most recently, Broadfoot has returned to aTyr Pharma as Chief Financial Officer. In this role, they are responsible for the financial planning and analysis, accounting, treasury, tax, and investor relations functions of the company.

Jill Broadfoot has a Bachelor of Science in Business Administration (Accounting) from San Diego State University. Jill is also a Certified Public Accountant (CPA) and a United States Coast Guard Captain.

They work with Sara L. Zaknoen - Director, Robert W. Ashworth - VP, Regulatory Affairs, and Leslie Nangle - VP, Research. Their manager is Sanjay S. Shukla, President & CEO.